In a study reported in the Journal of Clinical Oncology, Jabbar et al found that mass spectroscopy proteomic analysis of the pancreatic cyst fluid biomarkers mucin-5AC (MUC5AC), mucin-2 (MUC2), and prostate stem cell antigen (PSCA) identified cystic pancreatic cancers and precursor lesions with high accuracy.
In the study, biomarker candidates for malignant potential and high-grade dysplasia/cancer were identified via an explorative proteomic approach using cyst fluid samples from endoscopic ultrasound-guided aspiration in an initial cohort of 24 patients. Read more . . .